Whalesbook
📉 The Financial Deep Dive
The Numbers:
Alembic Pharmaceuticals Limited announced its Q3 FY'26 results, showcasing an 11% year-over-year revenue growth to INR 1,876 crores. For the nine-month period ending December 31, 2025, revenue climbed 12% YoY to approximately INR 5,500 crores.
The Quality:
Gross margins saw a slight compression, decreasing to 72% from 74% in the prior year, attributed to a shift in product mix and prevailing pricing challenges in key segments. Despite this, EBITDA before R&D and exceptional items demonstrated robust growth of 20% YoY, reaching INR 464 crores, or 25% of revenue, indicating improved operating leverage. R&D expenses escalated by 33% YoY to INR 165 crores, aligning with management's full-year guidance. Profit Before Tax (before exceptional items) grew 15% YoY to INR 205 crores, and Profit After Tax (before exceptional items) rose 21% YoY to INR 168 crores. However, a one-time provision of INR 42 crores for employee benefits, due to changes under the New Labour Code, impacted the reported Profit After Tax, resulting in a 4% YoY decline when adjusted for this exceptional item. Net working capital remained stable at INR 2,944 crores, and net debt saw a marginal decline to INR 1,213 crores.
The Grill:
While the earnings call did not feature aggressive analyst questioning that could be termed a 'grill', management addressed pricing pressures in U.S. generics and API segments. The strategic pivot towards a branded business in the U.S., with the upcoming launch of 'Pivya', was acknowledged as potentially impacting near-term profitability due to associated marketing and royalty expenses, though it is expected to scale over 12-18 months. Management also highlighted cost improvement programs mitigating margin pressures and expressed confidence in scaling utilization for injectable and onco capabilities through new agreements.
Risks & Outlook:
The company projects U.S. business growth between 10% to 12% for the full year. The introduction of 'Pivya', an oral antibiotic, in Q4 FY'26 marks a significant strategic shift towards a branded model in the U.S., a market where the company has historically focused on generics. While this move is expected to drive long-term value, it introduces near-term margin headwinds. In India, management anticipates the branded business growth to align with market rates by Q1 FY'27, driven by operational execution. R&D expenditure is expected to remain steady at 8-9% of revenue in FY'27. The company secured out-licensing and manufacturing agreements that should bolster its injectable and oncology segments.